Acute disseminated encephalomyelitis in two renal transplant patients: is there a role for Epstein-Barr virus reactivation?

2013 ◽  
Vol 19 (9) ◽  
pp. 1222-1225 ◽  
Author(s):  
N Caucheteux ◽  
A Maarouf ◽  
L Daelman ◽  
O Toupance ◽  
S Lavaud ◽  
...  
Keyword(s):  
Epstein Barr Virus ◽  
Demyelinating Disease ◽  
Acute Disseminated Encephalomyelitis ◽  
Virus Reactivation ◽  
Barr Virus ◽  
Transplant Patients ◽  
The Central Nervous System ◽  
Epstein Barr ◽  
Magnetic Resonance Imaging Mri ◽  
Epstein Barr Virus Reactivation

Acute disseminated encephalomyelitis (ADEM) is a rare inflammatory demyelinating disease of the central nervous system, usually occurring after a vaccination or infectious disease. It has been exceptionally described in transplanted patients. The pathophysiology remains incompletely understood. We report the clinical, biological and magnetic resonance imaging (MRI) presentation and evolution of two kidney-transplanted patients with ADEM associated with local Epstein-Barr virus (EBV) reactivation. ADEM may occur in transplanted patients with favorable evolution. Its pathophysiology is uncertain, and the implication of EBV is discussed.

scholarly journals A case of acute disseminated encephalomyelitis associated with Epstein-Barr virus reactivation during infliximab therapy

2010 ◽  
Vol 50 (7) ◽  
pp. 461-466 ◽  
Author(s):  
Maki Ueda ◽  
Takahisa Tateishi ◽  
Hiroshi Shigeto ◽  
Ryo Yamasaki ◽  
Yasumasa Ohyagi ◽  
...  
Keyword(s):  
Epstein Barr Virus ◽  
Acute Disseminated Encephalomyelitis ◽  
Infliximab Therapy ◽  
Virus Reactivation ◽  
Barr Virus ◽  
Epstein Barr ◽  
Epstein Barr Virus Reactivation

Valganciclovir suppressed Epstein Barr virus reactivation during immunosuppression with alemtuzumab

2014 ◽  
Vol 59 (4) ◽  
pp. 255-258 ◽  
Author(s):  
Harinder Gill ◽  
Yu-Yan Hwang ◽  
Thomas S.Y. Chan ◽  
Annie W.K. Pang ◽  
Anskar Y.H. Leung ◽  
...  
Keyword(s):  
Epstein Barr Virus ◽  
Virus Reactivation ◽  
Barr Virus ◽  
Epstein Barr ◽  
Epstein Barr Virus Reactivation

OR10 Genetic predisposition to interleukin-10 production influences epstein-barr virus reactivation after renal transplantation

2015 ◽  
Vol 76 ◽  
pp. 21
Author(s):  
Gaurav Tripathi ◽  
Abdulnaser Abadi ◽  
Poonam Dharmani-Khan ◽  
Lee Anne Tibbles ◽  
Serdar Yilmaz ◽  
...  
Keyword(s):  
Renal Transplantation ◽  
Genetic Predisposition ◽  
Epstein Barr Virus ◽  
Interleukin 10 ◽  
Virus Reactivation ◽  
Barr Virus ◽  
Epstein Barr ◽  
Epstein Barr Virus Reactivation

scholarly journals Clinical characteristics and outcomes of critically ill patients with acute COVID-19 with Epstein-Barr virus reactivation

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Yun Xie ◽  
Song Cao ◽  
Hui Dong ◽  
Hui Lv ◽  
Xiaolei Teng ◽  
...  
Keyword(s):  
Epstein Barr Virus ◽  
Mortality Rates ◽  
Virus Reactivation ◽  
Barr Virus ◽  
Ebv Reactivation ◽  
Imaging Characteristics ◽  
Single Center Study ◽  
Significant Difference ◽  
Epstein Barr ◽  
Epstein Barr Virus Reactivation

Abstract Background Our goal is to further elucidate the clinical condition and prognosis of patients with severe acute COVID-19 with EBV reactivation. Method This is a retrospective single-center study of COVID-19 patients admitted to the intensive care unit of Wuhan No. 3 Hospital (January 31 to March 27, 2020). According to whether Epstein-Barr virus reactivation was detected, the patients were divided into an EBV group and a Non-EBV group. Baseline data were collected including epidemiological, larithmics, clinical and imaging characteristics, and laboratory examination data. Results Of the 128 patients with COVID-19, 17 (13.3%) were infected with Epstein-Barr virus reactivation. In the symptoms,the rate of tachypnoea in the EBV group was apparently higher than that in the Non-EBV group. In lab tests, the lymphocyte and albumin of EBV group decreased more significantly than Non-EBV group, and the D-dimer and serum calcium of EBV group was higher than Non-EBV group. Regarding the infection index, CRP of EBV group was apparently above the Non-EBV group, and no significant difference was found in procalcitonin of the two groups. The incidence of respiratory failure, ARDS, and hypoproteinaemia of EBV group had more incidence than Non-EBV group. The 28-day and 14-day mortality rates of EBV group was significantly higher than that of Non-EBV group. Conclusions In the COVID-19 patients, patients with EBV reactivation had higher 28-day and 14-day mortality rates and received more immuno-supportive treatment than patients of Non-EBV group.

Sign in / Sign up

Export Citation Format

Share Document